Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | EVP,Pres LLY Oncology&HdCorpBD | February 09, 2026 | February 11, 2026 |
| Loxo Oncology, Inc.LOXO · Entity 160155 | Chief Operating Officer | February 15, 2019 | February 15, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date February 09, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,626.498 |
Reported balance
After 2026-02-09 transaction · row 1
1 source rowRow 1 · 2026-02-09 · Grant · Acquired 4,865.888 · Balance 26,626.498 |
| Common StockSEC Table I · non-derivative | IndirectVan Naarden Family Trust | 4,342 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,342 F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy SLAT | 5,302 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,302 F2: On February 5, 2026, the Reporting Person's spouse transferred 5,302 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person is the trustee and a beneficiary. The transfer included 1,000 spouse-held shares previously reported as directly held due to an administrative error. F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F2: On February 5, 2026, the Reporting Person's spouse transferred 5,302 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person is the trustee and a beneficiary. The transfer included 1,000 spouse-held shares previously reported as directly held due to an administrative error.
Loxo Oncology, Inc.
Report date February 15, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 1
1 source rowRow 1 · 2019-02-15 · Disposition to issuer · Disposed 19,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2024-06-18 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-15 · Disposition to issuer · Disposed 35,026 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.67 · Expires 2024-12-18 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-15 · Disposition to issuer · Disposed 78,943 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.69 · Expires 2025-12-15 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-15 · Disposition to issuer · Disposed 43,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.27 · Expires 2026-12-05 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-15 · Disposition to issuer · Disposed 74,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2027-03-14 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-15 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.88 · Expires 2028-01-03 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-02-15 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.77 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-02-15 · Disposition to issuer · Disposed 57,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 400 | $130.59 | $52,236.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,800 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.37 to $130.79 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 4,500 | $13.67 | $61,515.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,057 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · derivative · entry 22 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,943 Underlying: Common Stock · 2,057 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F16 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on January 19, 2015, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,443 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · derivative · entry 21 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,326 Underlying: Common Stock · 2,443 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F15 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 200 | $151.55 | $30,310.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 19 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 200 | $149.46 | $29,892.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 18 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,900 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F14 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.21 to $149.71 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 81 | $147.99 | $11,987.19 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 17 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 300 | $147.06 | $44,118.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 16 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,181 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F13 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.99 to $147.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 100 | $144.97 | $14,497.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 15 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,481 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 200 | $143.92 | $28,784.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 14 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,581 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F12 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.69 to $144.14 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 500 | $143.08 | $71,540.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 13 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,781 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.64 to $143.27 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 500 | $141.69 | $70,845.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 12 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,281 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.39 to $142.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 300 | $140.13 | $42,039.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,781 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.08 to $140.23 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,170 | $138.83 | $162,431.10 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 10 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,081 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.52 to $139.18 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 949 | $138.08 | $131,037.92 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 9 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,251 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.52 to $138.48 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 2,057 | $13.67 | $28,119.19 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 2,443 | $3.65 | $8,912.06 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · derivative · entry 20 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,769 Underlying: Common Stock · 5,500 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F15 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 200 | $156.45 | $31,290.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 600 | $155.30 | $93,180.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,900 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.04 to $155.44 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,500 | $154.00 | $231,000.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.75 to $154.69 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,644 | $152.49 | $250,693.56 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.21 to $152.94 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,556 | $151.71 | $236,060.76 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,644 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.19 to $152.14 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 17:13 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 5,500 | $3.65 | $20,064.00 |
DisclosureSEC source: 0001567619-18-007050 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 04, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 600 | $164.68 | $98,806.02 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · nonDerivative · entry 12 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F12 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.39 to $165.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,006 | $163.78 | $164,767.21 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · nonDerivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,300 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.38 to $164.31 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,194 | $162.70 | $194,264.99 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · nonDerivative · entry 10 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,306 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.22 to $163.21 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,100 | $161.52 | $177,672.55 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · nonDerivative · entry 9 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.22 to $162.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 600 | $160.62 | $96,373.02 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · nonDerivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,600 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.22 to $161.19 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 4,500 | $3.65 | $16,416.00 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · nonDerivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · derivative · entry 13 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,769 Underlying: Common Stock · 5,500 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F13 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 300 | $169.40 | $50,820.00 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · nonDerivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.39 to $169.41 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 2,300 | $168.85 | $388,346.95 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · nonDerivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.30 to $169.27 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 500 | $167.19 | $83,596.00 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · nonDerivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.09 to $167.57 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 400 | $165.89 | $66,354.00 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · nonDerivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,800 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.82 to $166.08 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 2,000 | $165.13 | $330,260.60 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,200 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.70 to $165.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2018 Filed Oct 5, 2018 16:46 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 5,500 | $3.65 | $20,064.00 |
DisclosureSEC source: 0001567619-18-003762 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · derivative · entry 13 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,269 Underlying: Common Stock · 4,500 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F12 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 300 | $167.49 | $50,246.01 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · nonDerivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.37 to $168.3699 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,500 | $166.63 | $249,952.05 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · nonDerivative · entry 10 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.26 to $167.2599 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 2,700 | $165.45 | $446,705.01 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · nonDerivative · entry 9 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.04 to $166.0399 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 4,500 | $3.65 | $16,416.00 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · nonDerivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · derivative · entry 12 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,769 Underlying: Common Stock · 5,500 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F12 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 600 | $171.03 | $102,616.02 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · nonDerivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.75 to $171.7499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 200 | $168.79 | $33,757.00 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · nonDerivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,300 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.78 to $169.7799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,000 | $167.39 | $167,392.00 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · nonDerivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.25 to $168.2499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,059 | $166.74 | $176,575.54 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · nonDerivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.17 to $167.1699 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,885 | $165.32 | $311,619.91 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · nonDerivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,559 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.94 to $165.9399 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 756 | $164.44 | $124,315.35 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,444 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.94 to $164.9399 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 18:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 5,500 | $3.65 | $20,064.00 |
DisclosureSEC source: 0001567619-18-002676 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.